However, considering that LN229 is a commercial non-stem GBM cell line [65,66], future studies should investigate the sensitivity of the astrocyte co-culture model with other GBM cell lines, including T98G, U251, U87 [66] and patient-derived primary GBM cell lines with or without stem cells [67], to TMZ in combination with NF-κB inhibitor Bay 11-7082 or different drug combinations. The gene discussed is NFKB1; the disease is glioblastoma.